Jochen Knolle - Pharvaris Chief COO

All Insiders . USA . 
Stock . Pharvaris BV . Stakeholders . Insider . Jochen Knolle
PHVS Stock  USD 25.36  0.82  3.34%   

Insider

Jochen Knolle is Chief COO of Pharvaris BV
Age 74
Phone31 712036410
Webhttps://pharvaris.com

Pharvaris Management Efficiency

The company has return on total asset (ROA) of (0.3685) % which means that it has lost $0.3685 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6509) %, meaning that it created substantial loss on money invested by shareholders. Pharvaris' management efficiency ratios could be used to measure how well Pharvaris manages its routine affairs as well as how well it operates its assets and liabilities.
Pharvaris BV currently holds 861.47 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Pharvaris BV has a current ratio of 12.59, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Pharvaris' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Leila MDPmv Pharmaceuticals
61
, MBAMolecular Partners AG
51
Brian MBAImmunocore Holdings
58
Thomas SchwerzmannMolecular Partners AG
N/A
David MackPmv Pharmaceuticals
63
Thomas ShenkPmv Pharmaceuticals
77
Amy JudgePreinImmunocore Holdings
N/A
Michael CarruthersEdgewise Therapeutics
67
Alan RussellEdgewise Therapeutics
55
Veit SchmelmerVor Biopharma
N/A
Alexander ZurcherMolecular Partners AG
50
Andreas EMBAMolecular Partners AG
58
Behrad DerakhshanEdgewise Therapeutics
45
Badreddin EdrisEdgewise Therapeutics
37
Annelise VuidepotImmunocore Holdings
N/A
Patrick AmstutzMolecular Partners AG
50
Jeffrey CPARallybio Corp
54
Sbastien DesprezImmunocore Holdings
N/A
Michael PitznerMolecular Partners AG
N/A
DPHIL MDVor Biopharma
51
Seth LewisMolecular Partners AG
N/A
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company was incorporated in 2015 and is based in Leiden, the Netherlands. Pharvaris is traded on NASDAQ Exchange in the United States. Pharvaris BV (PHVS) is traded on NASDAQ Exchange in USA. It is located in Grafenauweg 8, Zug, Switzerland, 6300 and employs 114 people. Pharvaris is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-0.65
Return On Asset-0.37

Pharvaris BV Leadership Team

Elected by the shareholders, the Pharvaris' board of directors comprises two types of representatives: Pharvaris inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharvaris. The board's role is to monitor Pharvaris' management team and ensure that shareholders' interests are well served. Pharvaris' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharvaris' outside directors are responsible for providing unbiased perspectives on the board's policies.
Peng MD, Chief Officer
Morgan Conn, Chief Officer
Jochen Knolle, Chief COO
CPA MBA, CEO CoFounder
Joan JD, Chief Officer
Stefan Abele, Chief Officer
Wim Souverijns, Chief Officer
Anne Lesage, Chief Officer
David JD, CFO Secretary
RA MSc, Head Officer
Maryann Cimino, Director Relations
Annick Deschoolmeester, Chief Officer

Pharvaris Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharvaris a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.65
Return On Asset-0.37
Current Valuation1.31 B
Shares Outstanding64.3 M
Shares Owned By Insiders5.31 %
Shares Owned By Institutions76.36 %
Number Of Shares Shorted404.97 K
Price To Book7.14 X
EBITDA(145.59 M)
Net Income(132.4 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Pharvaris Stock Analysis

When running Pharvaris' price analysis, check to measure Pharvaris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharvaris is operating at the current time. Most of Pharvaris' value examination focuses on studying past and present price action to predict the probability of Pharvaris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharvaris' price. Additionally, you may evaluate how the addition of Pharvaris to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY